Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enobia Pharma Inc.

Division of Alexion Pharmaceuticals Inc.
www.enobia.com

Latest From Enobia Pharma Inc.

No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company

Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.

BioPharmaceutical Business Strategies

Biotech raised $6bn in 2014 venture capital; most since 2007

Biotechnology companies ended 2014 with $6bn in new venture capital in their pockets, which was the biggest annual total since 2007, but that's after private startups and early-stage businesses raised $2bn in the fourth quarter alone – the biggest single-quarter total in at least 19 years.

Neurology Sweden

Alexion's hypophosphatasia drug asfotase alfa under FDA review

Alexion Pharmaceuticals said it has completed its rolling biologics license application submission to the FDA for asfotase alfa as a treatment for hypophosphatasia (HPP), a chronic and progressive ultra-rare metabolic disease, which can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.

Orthopedics

Sanford-Burnham Hopes $275 Million Gift Will Translate To Returns

As NIH funding becomes increasingly scarce, the La Jolla, Calif., research institute will use an anonymously donated gift to emphasize translational projects and take internal risk. Will it deliver returns that sustain the organization?

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • BioMep
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Alexion Pharmaceuticals Inc.
  • Senior Management
  • Robert Heft, PhD, Pres. & CEO
    Jeff Mack, VP, CFO
    Phillippe Crine, PhD, VP, CSO
  • Contact Info
  • Enobia Pharma Inc.
    Phone: (514) 596-2901
    2901 Rachel St. East, Ste. 23
    Montreal, H1W 4A4
    Canada
UsernamePublicRestriction

Register